Teladoc Appoints New CFO, Charles Schneider

TL;DR

Teladoc just hired a new CFO, Chuck Schneider, starting June 10th. New era for finances?

AI Summary

Teladoc Health, Inc. announced on June 5, 2024, the appointment of Charles R. "Chuck" Schneider as its new Chief Financial Officer, effective June 10, 2024. Schneider previously served as CFO of Accolade, Inc. and will receive an annual base salary of $475,000, along with other compensation and equity awards.

Why It Matters

The appointment of a new CFO can signal strategic shifts or a focus on financial stability and growth for the company.

Risk Assessment

Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty regarding future financial strategies and performance.

Key Numbers

• $475,000 — CFO Annual Base Salary (This is the starting base salary for the new Chief Financial Officer.)

Key Players & Entities

• Teladoc Health, Inc. (company) — Registrant
• Charles R. "Chuck" Schneider (person) — Newly appointed Chief Financial Officer
• $475,000 (dollar_amount) — Annual base salary for new CFO
• June 10, 2024 (date) — Effective date for new CFO
• Accolade, Inc. (company) — Previous employer of new CFO

FAQ

From the Filing

0001477449-24-000157.txt : 20240610 0001477449-24-000157.hdr.sgml : 20240610 20240610160515 ACCESSION NUMBER: 0001477449-24-000157 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20240605 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240610 DATE AS OF CHANGE: 20240610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Teladoc Health, Inc. CENTRAL INDEX KEY: 0001477449 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043705970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37477 FILM NUMBER: 241032663 BUSINESS ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 BUSINESS PHONE: 2036352002 MAIL ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 FORMER COMPANY: FORMER CONFORMED NAME: Teladoc, Inc. DATE OF NAME CHANGE: 20091123 8-K 1 tdoc-20240605.htm 8-K tdoc-20240605 FALSE 0001477449 0001477449 2024-06-05 2024-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) June 5, 2024 ___________________________________ Teladoc Health, Inc. (Exact name of registrant as specified in its charter) ___________________________________ Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commission File Number) 04-3705970 (I.R.S. Employer Identification Number) 2 Manhattanville Road Suite 203 Purchase , NY 10577 (Address of principal executive offices and zip code) ( 203 ) 635-2002 (Registrant's telephone number, including area code) ___________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common stock, par value $0.001 per share TDOC The New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act. Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02.     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Executive Officer and Director Effective June 10, 2024, Charles Divita, III joined Teladoc Health, Inc. (the “Company”) as its Chief Executive Officer. In connection with Mr. Divita's appointment to the position of Chief Executive Officer, Mala Murthy stepped down as acting Chief Executive Officer of the Company and will remain the Company's Chief Financial Officer. Als